Literature DB >> 9772924

Outcomes of recipients of both bone marrow and solid organ transplants. A review.

B Dey1, M Sykes, T R Spitzer.   

Abstract

In this review we examine the clinical outcomes of patients who have received both bone marrow transplantation (BMT) and solid organ transplantation (SOT) and discuss the possible immunologic consequences of the dual transplants. We collected cases through a comprehensive literature search (MEDLINE database, English literature only) covering the years 1990 through 1997 and correspondence with the International Bone Marrow Transplant Registry. Our study selected case reports of patients who have undergone both bone marrow and solid organ transplants; cases in which bone marrow transplantation was undertaken as an adjunct ot induce or augment donor-specific tolerance in a recipient to the transplanted organ were excluded. Clinical characteristics included patient's demographic information, underlying disorders for each transplant, source of donor organ or tissue, time between transplants, and immunosuppressive regimens used to prevent graft-versus-host disease (GVHD) or graft rejection. Clinical outcomes included patient survival, complications of transplantation, and donor-specific tolerance that was experienced in many cases. Twenty-one cases of SOT after BMT and 7 cases of BMT after SOT were reviewed. Solid organ transplantations included lung, liver, cardiac, and kidney for a variety of BMT-related complications including GVHD, hepatic veno-occlusive disease, chronic renal failure, end-stage pulmonary disease, and severe cardiomyopathy. Bone marrow transplants were performed following SOT for aplastic anemia and hematologic malignancies. Clinical outcomes for patients who received both BMT and SOT were variable and depended on transplant indication and degree of histocompatibility. Prior bone marrow transplantation may tolerize for a subsequent organ transplant from the same donor. Conversely, severe GVHD may follow BMT from human leukocyte antigen (HLA)-matched donors following SOT. The favorable survival in this high-risk group of patients may represent a literature review bias (that is, an undetermined number of unsuccessful cases may not have been reported). Nonetheless, dual transplantation is clearly feasible in selected cases.

Entities:  

Mesh:

Year:  1998        PMID: 9772924     DOI: 10.1097/00005792-199809000-00005

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  18 in total

Review 1.  A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host.

Authors:  C Mayaud; J Cadranel
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

Review 2.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

Review 3.  Immuno-intervention for the induction of transplantation tolerance through mixed chimerism.

Authors:  David H Sachs; Megan Sykes; Tatsuo Kawai; A Benedict Cosimi
Journal:  Semin Immunol       Date:  2011-08-11       Impact factor: 11.130

Review 4.  Primary cutaneous plasmacytoma after rejection of a transplanted kidney: case report and review of the literature.

Authors:  Gianpaolo Tessari; Fabio Fabbian; Chiara Colato; Fabio Benedetti; Massimo Franchini; Vittorio Ortalda; Lucia Cavallini; Annalisa Barba
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 5.  Translating transplantation tolerance in the clinic: where are we, where do we go?

Authors:  M Goldman; K Wood
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

6.  Novel diagnostics in renal transplantation.

Authors:  Niamh Kieran; Kim Muczynski; Vijayakrishna Vk Gadi
Journal:  Chimerism       Date:  2010-10

Review 7.  Human ES cells--haematopoiesis and transplantation strategies.

Authors:  D S Kaufman; J A Thomson
Journal:  J Anat       Date:  2002-03       Impact factor: 2.610

Review 8.  Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability.

Authors:  H G Prentice
Journal:  Support Care Cancer       Date:  2003-07-05       Impact factor: 3.603

9.  Clinical tolerance 2008.

Authors:  Allan D Kirk
Journal:  Transplantation       Date:  2009-04-15       Impact factor: 4.939

Review 10.  Transplantation tolerance: from theory to clinic.

Authors:  Ephraim J Fuchs
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.